已受理,完成質(zhì)量復(fù)核,轉(zhuǎn)CDE。已在歐洲、美國(guó)登記注冊(cè)。索利那新用于改善膀胱過(guò)度活動(dòng)癥引發(fā)的尿頻、尿急和尿失禁等癥狀。本品對(duì)膀胱M3受體有高新和力,能選擇性抑制膀胱節(jié)律性收縮而不影響唾液分泌,吸收不受食物影響,主要經(jīng)CY3A4代謝,老年患者無(wú)需調(diào)整劑量。與達(dá)非那新相比較,其對(duì)膀胱膽堿M3受體的選擇性更專一,對(duì)受體抑制活性更強(qiáng),用藥安全性和耐受性較好,對(duì)中樞神經(jīng)、人體認(rèn)知功能的影響及心血管危險(xiǎn)性較低。
安森博有近二十年進(jìn)口藥品注冊(cè)經(jīng)驗(yàn),80多個(gè)進(jìn)口藥品成功注冊(cè)案例。
業(yè)務(wù)范圍:1、進(jìn)口藥品代理;2、進(jìn)口藥品注冊(cè)委托服務(wù);3、尋找進(jìn)口制劑國(guó)內(nèi)銷售合作伙伴。
如您對(duì)我們的進(jìn)口原料藥感興趣,只需采購(gòu)即可,我們負(fù)責(zé)進(jìn)口原料藥注冊(cè)等。目前我公司已有近30個(gè)進(jìn)口原料藥在CDE排隊(duì)待審,50多個(gè)進(jìn)口原料藥的資料在整理中。已有60多家國(guó)內(nèi)制劑廠采購(gòu)我們的原料藥。
我們代理的進(jìn)口制劑,已經(jīng)在歐美已經(jīng)或即將上市銷售,質(zhì)量可靠,期待與您合作。
We are a trade company. We are very strong in registration and promotion of import drugs in China, with decades of registration experience and over 86 Licenses procured successfully.
We submitted about 10 import drug applications per year since 2011;
Our knowledge, experience and good working relationship with the regulatory department help us to speed up regulatory approvals and to provide sound support for our formulation customers.
We procured 5 new IDLs in 2010, among which one license was obtained within 10 months and another was obtained within 12 months.
We do not manufacture API and formulation, only focus on registration and promotion of import drug in China.
- ONC201 (TIC10) 在產(chǎn)品研發(fā)和動(dòng)
- 藥用級(jí)氨基己酸原料國(guó)藥準(zhǔn)字GMP
- 藥用級(jí)氫氯噻嗪原料國(guó)藥準(zhǔn)字GMP
- 藥用級(jí)鹽酸金剛烷胺原料國(guó)藥準(zhǔn)字
- 藥用級(jí)豬膽粉CP藥典標(biāo)準(zhǔn)GMP認(rèn)證
- 藥用級(jí)磷酸苯丙哌林原料國(guó)藥準(zhǔn)字
- 藥用級(jí)人工牛黃CP藥典標(biāo)準(zhǔn)
- 藥用級(jí)維生素K1原料藥CP藥典標(biāo)準(zhǔn)
- 藥用級(jí)硫酸慶大霉素的作用機(jī)制,
- 藥用級(jí)鹽酸烏拉地爾原料CP藥典標(biāo)